Macquarie Group
NTLA icon

Macquarie Group’s Intellia Therapeutics NTLA Stock Holding History

Macquarie Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$345K – 1282
2025
Q3 		$345K Hold
20,000
– – ﹤0.01% 1450
2025
Q2 		$188K Hold
20,000
– – ﹤0.01% 1540
2025
Q1 		$142K Hold
20,000
– – ﹤0.01% 1546
2024
Q4 		$233K Hold
20,000
– – ﹤0.01% 1504
2024
Q3 		$411K Hold
20,000
– – ﹤0.01% 1498
2024
Q2 		$448K Hold
20,000
– – ﹤0.01% 1475
2024
Q1 		$550K Hold
20,000
– – ﹤0.01% 1436
2023
Q4 		$610K Hold
20,000
– – ﹤0.01% 1448
2023
Q3 		$632K Hold
20,000
– – ﹤0.01% 1413
2023
Q2 		$816K Hold
20,000
– – ﹤0.01% 1393
2023
Q1 		$745K Hold
20,000
– – ﹤0.01% 1413
2022
Q4 		$698K Sell
20,000
-479
-2% -$22.8K ﹤0.01% 1475
2022
Q3 		$1.19M Sell
20,479
-793
-4% -$49.2K ﹤0.01% 1382
2022
Q2 		$1.1M Hold
21,272
– – ﹤0.01% 1461
2022
Q1 		$1.54M Hold
21,272
– – ﹤0.01% 1442
2021
Q4 		$2.52M Sell
21,272
-287
-1% -$36K ﹤0.01% 1305
2021
Q3 		$2.89M Buy
21,559
+730
+4% +$111K ﹤0.01% 1258
2021
Q2 		$3.37M Sell
20,829
-528
-2% -$41.1K ﹤0.01% 1250
2021
Q1 		$1.71M Sell
21,357
-416
-2% -$27.9K ﹤0.01% 1249
2020
Q4 		$1.18M Hold
21,773
– – ﹤0.01% 1269
2020
Q3 		$433K Hold
21,773
– – ﹤0.01% 1432
2020
Q2 		$457K Buy
+21,773
New +$370K ﹤0.01% 1369
2019
Q1 		– Sell
-300
Closed -$4K – 1919
2018
Q4 		$4K Buy
300
+200
+200% +$3.72K ﹤0.01% 2137
2018
Q3 		$3K Sell
100
-3,600
-97% -$105K ﹤0.01% 2111
2018
Q2 		$101K Buy
+3,700
New +$89.6K ﹤0.01% 1841

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Macquarie Group's NTLA Position: Q4 2025 in Review

Macquarie Group sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 20,000 shares — an estimated $345K sold.

Macquarie Group first reported a position in NTLA in Q2 2018 and held it in 25 quarters. The position peaked at $3.37M in Q2 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Macquarie Group reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 20,000 Intellia Therapeutics shares in Q4 2025, an estimated $345K.
  • Macquarie Group first reported a position in Intellia Therapeutics in Q2 2018 and held it in 25 quarters.
  • Macquarie Group's Intellia Therapeutics position peaked at $3.37M in Q2 2021.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.